Charles Rudin, MD, PhD: We were interested to see the safety data from both of these trials, the IMpower133 trial and the CASPIAN trial. They’re actually quite reassuring. There were immunologic adverse events associated with the immunotherapy, but they were nothing we hadn’t seen before and nothing that was unexpected. In general, these regimens are reasonably well tolerated with appropriate management. It is important to be monitoring patients for symptomatology associated with immunotherapy. This can include inflammation of the colon associated with diarrhea, what we call colitis or pneumonitis, which is a particularly problematic complication in patients with lung cancer. That’s inflammation of the lungs and can be associated with shortness of breath. It’s important to recognize these and intervene on them early if they’re seen.

In my mind, the main message from these 2 key trials, the IMpower133 and the CASPIAN trials, are very similar. There are slight differences in the study design, but in general these were very similar cohorts, very similar trial designs, and very similar outcomes. To my mind, as a practicing oncologist, these are mutually reinforcing and really help to support each other and give us greater confidence in the outcome.

Transcript Edited for Clarity